false--12-31Q30000914139YesYes0000914139prkr:ContingentPaymentObligationMemberus-gaap:UnsecuredDebtMember2021-09-300000914139prkr:ContingentPaymentObligationMemberus-gaap:UnsecuredDebtMember2020-12-310000914139prkr:ContingentPaymentObligationMemberus-gaap:UnsecuredDebtMember2019-12-310000914139prkr:ThirdPartyMember2021-06-012021-06-3000009141392021-03-012021-03-310000914139prkr:ThirdPartyMember2021-01-012021-01-310000914139prkr:SecuritiesPurchaseAgreementsMember2021-01-012021-01-310000914139prkr:NonEmployeeDirectorsMemberus-gaap:EmployeeStockOptionMember2021-01-012021-09-300000914139prkr:NamedExecutiveEmployeesMemberus-gaap:EmployeeStockOptionMember2021-01-012021-09-300000914139us-gaap:CommonStockMember2021-09-300000914139us-gaap:AdditionalPaidInCapitalMember2021-09-300000914139prkr:AccumulatedDeficitMember2021-09-300000914139us-gaap:CommonStockMember2021-06-300000914139us-gaap:AdditionalPaidInCapitalMember2021-06-300000914139prkr:AccumulatedDeficitMember2021-06-3000009141392021-06-300000914139srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AdditionalPaidInCapitalMember2020-12-310000914139srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberprkr:AccumulatedDeficitMember2020-12-310000914139us-gaap:CommonStockMember2020-12-310000914139us-gaap:AdditionalPaidInCapitalMember2020-12-310000914139prkr:AccumulatedDeficitMember2020-12-310000914139us-gaap:CommonStockMember2020-09-300000914139us-gaap:AdditionalPaidInCapitalMember2020-09-300000914139prkr:AccumulatedDeficitMember2020-09-300000914139us-gaap:CommonStockMember2020-06-300000914139us-gaap:AdditionalPaidInCapitalMember2020-06-300000914139prkr:AccumulatedDeficitMember2020-06-3000009141392020-06-300000914139us-gaap:CommonStockMember2019-12-310000914139us-gaap:AdditionalPaidInCapitalMember2019-12-310000914139prkr:AccumulatedDeficitMember2019-12-310000914139prkr:SecuritiesPurchaseAgreementsMember2021-01-310000914139us-gaap:EmployeeStockOptionMember2021-01-012021-09-300000914139prkr:ContingentPaymentObligationMemberus-gaap:SecuredDebtMember2021-09-300000914139prkr:ContingentPaymentObligationMemberus-gaap:SecuredDebtMember2020-12-310000914139prkr:ContingentPaymentObligationMemberus-gaap:SecuredDebtMember2019-12-310000914139us-gaap:UnsecuredDebtMember2021-01-012021-09-300000914139us-gaap:SecuredDebtMember2021-01-012021-09-300000914139us-gaap:SecuredDebtMemberprkr:MintzMember2021-03-292021-03-290000914139prkr:MintzMember2021-03-012021-03-310000914139us-gaap:UnsecuredDebtMember2021-01-012021-01-310000914139prkr:PaycheckProtectionProgramLoanMember2020-05-012020-05-310000914139us-gaap:FairValueInputsLevel2Memberus-gaap:ConvertibleDebtMember2021-09-300000914139us-gaap:FairValueInputsLevel3Memberprkr:UnsecuredContingentPaymentObligationMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-300000914139us-gaap:FairValueInputsLevel3Memberprkr:SecuredContingentPaymentObligationMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-300000914139prkr:UnsecuredContingentPaymentObligationMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-300000914139prkr:SecuredContingentPaymentObligationMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-300000914139us-gaap:FairValueInputsLevel3Memberprkr:UnsecuredContingentPaymentObligationMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914139us-gaap:FairValueInputsLevel3Memberprkr:SecuredContingentPaymentObligationMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914139prkr:UnsecuredContingentPaymentObligationMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914139prkr:SecuredContingentPaymentObligationMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914139prkr:ConsultantTwoMember2021-08-102021-08-100000914139prkr:ThirdPartyMember2021-04-012021-04-300000914139prkr:ConsultantsMember2021-04-012021-04-300000914139prkr:ConsultantOneMember2021-03-092021-03-0900009141392021-01-012021-01-310000914139prkr:ParkervisionV.IntelIiWesternDistrictOfTexasMember2020-06-012020-06-300000914139prkr:ParkervisionV.IntelIiWesternDistrictOfTexasMember2020-07-012020-07-310000914139prkr:ParkervisionV.IntelWesternDistrictOfTexasMember2020-05-012020-05-310000914139prkr:ParkervisionV.IntelWesternDistrictOfTexasMember2020-02-012020-02-290000914139prkr:ParkervisionV.AppleAndQualcommMiddleDistrictOfFloridaMember2015-12-012015-12-310000914139srt:WeightedAverageMemberus-gaap:UnsecuredDebtMember2021-09-300000914139srt:WeightedAverageMemberus-gaap:SecuredDebtMember2021-09-300000914139srt:MinimumMemberus-gaap:UnsecuredDebtMember2021-09-300000914139srt:MinimumMemberus-gaap:SecuredDebtMember2021-09-300000914139srt:MaximumMemberus-gaap:UnsecuredDebtMember2021-09-300000914139srt:MaximumMemberus-gaap:SecuredDebtMember2021-09-300000914139us-gaap:DebtInstrumentRedemptionPeriodTwoMemberus-gaap:ConvertibleDebtMember2021-01-012021-09-300000914139us-gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:ConvertibleDebtMember2021-01-012021-09-300000914139us-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:ConvertibleDebtMember2021-01-012021-09-300000914139us-gaap:DebtInstrumentRedemptionPeriodFourMemberus-gaap:ConvertibleDebtMember2021-01-012021-09-300000914139prkr:PromissoryNotesMemberus-gaap:UnsecuredDebtMemberprkr:SterneKesslerGoldsteinFoxPllcMember2021-01-012021-09-300000914139srt:WeightedAverageMemberus-gaap:UnsecuredDebtMemberprkr:EstimatedProbabilitiesMember2021-09-300000914139srt:WeightedAverageMemberus-gaap:SecuredDebtMemberprkr:EstimatedProbabilitiesMember2021-09-300000914139srt:MinimumMemberus-gaap:UnsecuredDebtMemberprkr:EstimatedProbabilitiesMember2021-09-300000914139srt:MinimumMemberus-gaap:SecuredDebtMemberprkr:EstimatedProbabilitiesMember2021-09-300000914139srt:MaximumMemberus-gaap:UnsecuredDebtMemberprkr:EstimatedProbabilitiesMember2021-09-300000914139srt:MaximumMemberus-gaap:SecuredDebtMemberprkr:EstimatedProbabilitiesMember2021-09-300000914139us-gaap:SecuredDebtMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-09-300000914139us-gaap:SecuredDebtMemberus-gaap:MeasurementInputEntityCreditRiskMember2021-09-300000914139us-gaap:SecuredDebtMemberus-gaap:MeasurementInputDiscountRateMember2021-09-300000914139us-gaap:SecuredDebtMemberprkr:MeasurementInputLitigationInherentRiskMember2021-09-300000914139srt:MinimumMemberprkr:ConvertibleNotesDatedMemberus-gaap:ConvertibleDebtMember2021-01-012021-09-300000914139srt:MinimumMemberprkr:ConvertibleNotesDatedBMemberus-gaap:ConvertibleDebtMember2021-01-012021-09-300000914139srt:MaximumMemberprkr:ConvertibleNotesDatedMemberus-gaap:ConvertibleDebtMember2021-01-012021-09-300000914139srt:MaximumMemberprkr:ConvertibleNotesDatedBMemberus-gaap:ConvertibleDebtMember2021-01-012021-09-300000914139prkr:ConvertibleNotesDatedSeptember192018Memberus-gaap:ConvertibleDebtMember2021-01-012021-09-300000914139prkr:ConvertibleNotesDatedSeptember102018Memberus-gaap:ConvertibleDebtMember2021-01-012021-09-300000914139prkr:ConvertibleNotesDatedEMemberus-gaap:ConvertibleDebtMember2021-01-012021-09-300000914139prkr:ConvertibleNotesDatedDMemberus-gaap:ConvertibleDebtMember2021-01-012021-09-300000914139prkr:ConvertibleNotesDatedCMemberus-gaap:ConvertibleDebtMember2021-01-012021-09-300000914139prkr:PromissoryNotesMemberus-gaap:UnsecuredDebtMemberprkr:SterneKesslerGoldsteinFoxPllcMember2021-09-300000914139prkr:ConvertibleNotesDatedSeptember192018Memberus-gaap:ConvertibleDebtMember2021-09-300000914139prkr:ConvertibleNotesDatedSeptember102018Memberus-gaap:ConvertibleDebtMember2021-09-300000914139prkr:ConvertibleNotesDatedMemberus-gaap:ConvertibleDebtMember2021-09-300000914139prkr:ConvertibleNotesDatedEMemberus-gaap:ConvertibleDebtMember2021-09-300000914139prkr:ConvertibleNotesDatedDMemberus-gaap:ConvertibleDebtMember2021-09-300000914139prkr:ConvertibleNotesDatedCMemberus-gaap:ConvertibleDebtMember2021-09-300000914139prkr:ConvertibleNotesDatedBMemberus-gaap:ConvertibleDebtMember2021-09-300000914139prkr:ConvertibleNotesDatedSeptember192018Memberus-gaap:ConvertibleDebtMember2020-12-310000914139prkr:ConvertibleNotesDatedSeptember102018Memberus-gaap:ConvertibleDebtMember2020-12-310000914139prkr:ConvertibleNotesDatedMemberus-gaap:ConvertibleDebtMember2020-12-310000914139prkr:ConvertibleNotesDatedEMemberus-gaap:ConvertibleDebtMember2020-12-310000914139prkr:ConvertibleNotesDatedDMemberus-gaap:ConvertibleDebtMember2020-12-310000914139prkr:ConvertibleNotesDatedCMemberus-gaap:ConvertibleDebtMember2020-12-310000914139prkr:ConvertibleNotesDatedBMemberus-gaap:ConvertibleDebtMember2020-12-310000914139us-gaap:ConvertibleDebtMember2021-01-012021-09-300000914139us-gaap:ConvertibleDebtMember2021-09-300000914139us-gaap:ConvertibleDebtMember2020-12-310000914139prkr:ContingentPaymentRightsMember2021-01-012021-09-300000914139prkr:AccumulatedDeficitMember2021-07-012021-09-300000914139prkr:AccumulatedDeficitMember2021-01-012021-09-300000914139prkr:AccumulatedDeficitMember2020-07-012020-09-3000009141392020-07-012020-09-300000914139prkr:AccumulatedDeficitMember2020-01-012020-09-3000009141392021-09-2800009141392021-09-270000914139srt:WeightedAverageMember2021-09-3000009141392020-09-3000009141392019-12-310000914139us-gaap:WarrantMember2021-01-012021-09-300000914139us-gaap:EmployeeStockOptionMember2021-01-012021-09-300000914139us-gaap:ConvertibleDebtSecuritiesMember2021-01-012021-09-300000914139us-gaap:WarrantMember2020-01-012020-09-300000914139us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-300000914139us-gaap:EmployeeStockOptionMember2020-01-012020-09-300000914139us-gaap:ConvertibleDebtSecuritiesMember2020-01-012020-09-300000914139srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:ConvertibleDebtMember2020-01-012020-12-3100009141392021-07-012021-09-300000914139us-gaap:AccountingStandardsUpdate202006Member2020-12-310000914139country:DE2021-09-300000914139srt:MinimumMemberprkr:ContingentPaymentObligationMember2021-01-012021-09-300000914139srt:MaximumMemberprkr:ContingentPaymentObligationMember2021-01-012021-09-300000914139prkr:ParkervisionV.QualcommMiddleDistrictOfFloridaMember2017-03-012017-03-3100009141392018-03-012018-03-310000914139prkr:ParkervisionV.QualcommMiddleDistrictOfFloridaMember2019-07-012019-07-310000914139us-gaap:CommonStockMember2021-07-012021-09-300000914139us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300000914139us-gaap:CommonStockMember2021-01-012021-09-300000914139us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300000914139us-gaap:CommonStockMember2020-07-012020-09-300000914139us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300000914139us-gaap:CommonStockMember2020-01-012020-09-300000914139us-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-300000914139prkr:ParkervisionV.QualcommMiddleDistrictOfFloridaMember2021-01-012021-09-3000009141392020-10-012020-10-3100009141392020-01-012020-09-300000914139srt:WeightedAverageMemberus-gaap:UnsecuredDebtMember2021-01-012021-09-300000914139srt:WeightedAverageMemberus-gaap:SecuredDebtMember2021-01-012021-09-300000914139srt:MinimumMemberus-gaap:UnsecuredDebtMember2021-01-012021-09-300000914139srt:MinimumMemberus-gaap:SecuredDebtMember2021-01-012021-09-300000914139srt:MaximumMemberus-gaap:UnsecuredDebtMember2021-01-012021-09-300000914139srt:MaximumMemberus-gaap:SecuredDebtMember2021-01-012021-09-300000914139prkr:ContingentPaymentObligationMemberus-gaap:UnsecuredDebtMember2021-01-012021-09-300000914139prkr:ContingentPaymentObligationMemberus-gaap:SecuredDebtMember2021-01-012021-09-300000914139prkr:ContingentPaymentObligationMemberus-gaap:UnsecuredDebtMember2020-01-012020-12-310000914139prkr:ContingentPaymentObligationMemberus-gaap:SecuredDebtMember2020-01-012020-12-310000914139us-gaap:SecuredDebtMemberprkr:MintzMember2020-12-3100009141392020-01-012020-12-3100009141392021-09-3000009141392021-03-310000914139prkr:ParkervisionV.QualcommMiddleDistrictOfFloridaMembersrt:MaximumMember2020-04-012020-04-300000914139prkr:ParkervisionV.QualcommMiddleDistrictOfFloridaMember2020-04-012020-04-300000914139prkr:ParkervisionV.AppleAndQualcommMiddleDistrictOfFloridaMembersrt:MaximumMember2019-07-012019-07-310000914139prkr:ParkervisionV.AppleAndQualcommMiddleDistrictOfFloridaMember2019-07-012019-07-310000914139us-gaap:ConvertibleDebtMemberus-gaap:CommonStockMember2021-07-012021-09-300000914139us-gaap:ConvertibleDebtMemberus-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300000914139us-gaap:ConvertibleDebtMemberus-gaap:CommonStockMember2021-01-012021-09-300000914139us-gaap:ConvertibleDebtMemberus-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300000914139us-gaap:ConvertibleDebtMemberus-gaap:CommonStockMember2020-07-012020-09-300000914139us-gaap:ConvertibleDebtMemberus-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300000914139us-gaap:ShortTermDebtMemberus-gaap:CommonStockMember2020-01-012020-09-300000914139us-gaap:ShortTermDebtMemberus-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-300000914139us-gaap:ConvertibleDebtMemberus-gaap:CommonStockMember2020-01-012020-09-300000914139us-gaap:ConvertibleDebtMemberus-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-3000009141392020-12-3100009141392021-11-1000009141392021-01-012021-09-30iso4217:USDxbrli:sharesxbrli:pureprkr:claimprkr:itemiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

 x 

QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 ¨ 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________to____________

Commission file number 000-22904

PARKERVISION, INC.

(Exact name of registrant as specified in its charter)

Florida

59-2971472

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No)

4446-1A Hendricks Avenue, Suite 354

Jacksonville, Florida 32207

(Address of principal executive offices)

(904) 732-6100

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

Common Stock, $.01 par value

PRKR

OTCQB

Common Stock Rights

OTCQB

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x   No ¨ .

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such file). Yes x   No ¨ .

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer  ¨

Accelerated filer  ¨

Non-accelerated filer   x

Smaller reporting company  x

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨   No x

As of November 10, 2021, 75,189,175 shares of the issuer’s common stock, $.01 par value, were outstanding. 


TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

2

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

20

Item 3. Quantitative and Qualitative Disclosures About Market Risk

23

Item 4. Controls and Procedures

23

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

24

Item 1A. Risk Factors

24

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

24

Item 3. Defaults Upon Senior Securities

24

Item 4. Mine Safety Disclosures

24

Item 5. Other Information

24

Item 6. Exhibits

25

SIGNATURES

26

1


PART I - FINANCIAL INFORMATION

ITEM 1. Financial Statements (Unaudited)

PARKERVISION, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(in thousands, except par value data)

September 30,

December 31,

2021

2020

CURRENT ASSETS:

Cash and cash equivalents

$

760

$

1,627

Prepaid expenses

707

599

Other current assets

18

8

Total current assets

1,485

2,234

Operating lease right-of-use assets

8

10

Intangible assets, net

1,887

2,170

Property, equipment and other assets, net

21

42

Total assets

$

3,401

$

4,456

CURRENT LIABILITIES:

Accounts payable

$

589

$

4,318

Accrued expenses:

Salaries and wages

58

19

Professional fees

103

128

Statutory court costs

-

251

Other accrued expenses

483

936

Related party note payable, current portion

103

100

Secured note payable, current portion

-

26

Unsecured notes payable

-

65

Operating lease liabilities, current portion

164

146

Total current liabilities

1,500

5,989

LONG-TERM LIABILITIES:

Secured contingent payment obligation

35,940

33,057

Convertible notes

3,015

3,018

Related party note payable, net of current portion

633

703

Unsecured contingent payment obligations

5,747

5,222

Operating lease liabilities, net of current portion

34

159

Other long-term liabilities

1

129

Total long-term liabilities

45,370

42,288

Total liabilities

46,870

48,277

SHAREHOLDERS' DEFICIT:

Common stock, $0.01 par value, 150,000 and 140,000 shares authorized, 74,743 and 58,591 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively

747

586

Additional paid-in capital

385,843

376,954

Accumulated deficit

(430,059)

(421,361)

Total shareholders' deficit

(43,469)

(43,821)

Total liabilities and shareholders' deficit

$

3,401

$

4,456

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

2


PARKERVISION, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(UNAUDITED)

(in thousands, except per share data)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2021

2020

2021

2020

Licensing revenue

$

144

$

-

$

144

$

-

Cost of sales

(1)

-

(1)

-

Gross margin

143

-

143

-

Selling, general and administrative expenses

2,024

1,445

6,152

9,268

Total operating expenses

2,024

1,445

6,152

9,268

Other income

19

1

213

1

Interest expense

(70)

(119)

(185)

(420)

Change in fair value of contingent payment obligations

(172)

(105)

(2,996)

(3,487)

Total interest and other

(223)

(223)

(2,968)

(3,906)

Net loss

(2,104)

(1,668)

(8,977)

(13,174)

Other comprehensive loss, net of tax

-

-

-

-

Comprehensive loss

$

(2,104)

$

(1,668)

$

(8,977)

$

(13,174)

Basic and diluted net loss per common share

$

(0.03)

$

(0.03)

$

(0.13)

$

(0.29)

Weighted average common shares outstanding

73,868

50,530

69,869

44,772

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3


PARKERVISION, INC.

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ DEFICIT

(UNAUDITED)

(in thousands)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2021

2020

2021

2020

Total shareholders' deficit, beginning balances

$

(42,949)

$

(38,334)

$

(43,821)

$

(33,097)

Common stock

Beginning balances

727

491

586

341

Issuance of common stock and warrants in public and private offerings, net of issuance costs and initial fair value of contingent payment rights

-

15

62

97

Issuance of common stock upon exercise of options and warrants

6

10

58

35

Issuance of common stock and warrants for services

2

1

9

7

Issuance of common stock upon conversion and payment of interest-in-kind on convertible debt

12

2

30

10

Issuance of common stock upon conversion of short-term loans and payables

-

-

-

22

Share-based compensation, net of shares withheld for taxes

-

1

2

8

Ending balances

747

520

747

520

Additional paid-in capital

Beginning balances

384,279

374,464

376,954

368,345

Cumulative effect of change in accounting principle

-

-

(1,126)

-

Issuance of common stock and warrants in public and private offerings, net of issuance costs and initial fair value of contingent payment rights

-

215

4,712

3,751

Issuance of common stock upon exercise of options and warrants

108

340

878

1,190

Issuance of common stock and warrants for services

208

25

829

257

Issuance of convertible debt with beneficial conversion feature

-

-

-

173

Issuance of common stock upon conversion and payment of interest-in-kind on convertible debt

502

87

1,029

340

Issuance of common stock upon conversion of short-term loans and payables

-

-

-

318

Share-based compensation, net of shares withheld for taxes

746

239

2,567

996

Ending balances

385,843

375,370

385,843

375,370

Accumulated deficit

Beginning balances

(427,955)

(413,289)

(421,361)

(401,783)

Cumulative effect of change in accounting principle

-

-

279

-

Comprehensive loss for the period

(2,104)

(1,668)

(8,977)

(13,174)

Ending balances

(430,059)

(414,957)

(430,059)

(414,957)

Total shareholders' deficit, ending balances

$

(43,469)

$

(39,067)

$

(43,469)

$

(39,067)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4


PARKERVISION, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(in thousands)

Nine Months Ended

September 30,

2021

2020

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss

$

(8,977)

$

(13,174)

Adjustments to reconcile net loss to net cash used in
   operating activities:

Depreciation and amortization

281

497

Share-based compensation

2,569

1,004

Noncash lease expense

2

60

Loss on changes in fair value of contingent payment obligations

2,996

3,487

Loss on disposal/impairment of equipment and intangible assets

25

413

Loan forgiveness

(194)

-

Noncash expense for amendment of equity-related agreements

-

2,211

Changes in operating assets and liabilities:

Prepaid expenses and other assets

624

192

Accounts payable and accrued expenses

(4,139)

1,302

Operating lease liabilities

(107)

(174)

Total adjustments

2,057

8,992

Net cash used in operating activities

(6,920)

(4,182)

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchases of property and equipment

(2)

(3)

Net cash used in investing activities

(2)

(3)

CASH FLOWS FROM FINANCING ACTIVITIES:

Net proceeds from issuance of common stock, including contingent payment rights, in private offerings

5,186

3,057

Net proceeds from exercise of options and warrants

936

1,225

Net proceeds from debt financings

-

1,244

Principal payments on long-term debt

(67)

(1,251)

Net cash provided by financing activities

6,055

4,275

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS

(867)

90

CASH AND CASH EQUIVALENTS, beginning of period

1,627

57

CASH AND CASH EQUIVALENTS, end of period

$

760

$

147

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5


PARKERVISION, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1. Description of Business

ParkerVision, Inc. and its wholly-owned German subsidiary, ParkerVision GmbH (collectively “ParkerVision”, “we” or the “Company”), is in the business of innovating fundamental wireless technologies and products.

We have designed and developed proprietary radio frequency (“RF”) technologies and integrated circuits and license those technologies to others for use in wireless communication products. We have expended significant financial and other resources to research and develop our RF technologies and to obtain patent protection for those technologies in the United States of America (“U.S.”) and certain foreign jurisdictions. We believe certain patents protecting our proprietary technologies have been broadly infringed by others, and therefore the primary focus of our business plan is the enforcement of our intellectual property rights through patent infringement litigation and licensing efforts. We currently have patent enforcement actions ongoing in various U.S. district courts against providers of mobile handsets, smart televisions and other WiFi products and, in certain cases, their chip suppliers for the infringement of a number of our RF patents. We have made significant investments in developing and protecting our technologies.

2. Liquidity and Going Concern

Our accompanying condensed consolidated financial statements were prepared assuming we would continue as a going concern, which contemplates that we will continue in operation for the foreseeable future and will be able to realize assets and settle liabilities and commitments in the normal course of business for a period of at least one year from the issuance date of these condensed consolidated financial statements. These condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that could result should we be unable to continue as a going concern.

We have incurred significant losses from operations and negative cash flows from operations in every year since inception and have utilized the proceeds from the sales of debt and equity securities and contingent funding arrangements with third parties to fund our operations, including the cost of litigation. For the nine months ended September 30, 2021, we incurred a net loss of approximately $9.0 million and negative cash flows from operations of approximately $6.9 million. At September 30, 2021, we had cash and cash equivalents of approximately $0.8 million and an accumulated deficit of approximately $430.1 million. Additionally, a significant amount of future proceeds that we may receive from our patent enforcement and licensing programs will first be utilized to repay borrowings and legal fees and expenses under our contingent funding arrangements. These circumstances raise substantial doubt about our ability to continue to operate as a going concern for a period of one year following the issue date of these condensed consolidated financial statements.

For the nine months ended September 30, 2021, we received aggregate net proceeds from debt and equity financings of approximately $5.2 million and proceeds from the exercise of outstanding options and warrants of approximately $0.9 million. We used a significant portion of these proceeds to pay current obligations resulting in a reduction in our accounts payable and accrued expenses of approximately $4.1 million for the nine months ended September 30, 2021. Our current capital resources are not sufficient to meet our short-term liquidity needs and we will be required to seek additional capital.

6


Our ability to meet our liquidity needs for the next twelve months is dependent upon (i) our ability to successfully negotiate licensing agreements and/or settlements relating to the use of our technologies by others in excess of our contingent payment obligations, (ii) our ability to control operating costs, and/or (iii) our ability to obtain additional debt or equity financing, if needed. We expect that proceeds received by us from patent enforcement actions and technology licenses over the next twelve months may not be sufficient to cover our working capital requirements.

We expect to continue to invest in the support of our patent enforcement and licensing programs. The long-term continuation of our business plan is dependent upon the generation of sufficient revenues from our technologies and/or products to offset expenses and contingent payment obligations. In the event that we do not generate sufficient revenues, we will be required to obtain additional funding through public or private debt or equity financing or contingent fee arrangements and/or reduce operating costs. Failure to generate sufficient revenues, raise additional capital through debt or equity financings or contingent fee arrangements, and/or reduce operating costs will have a material adverse effect on our ability to meet our long-term liquidity needs and achieve our intended long-term business objectives.

 

3. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements for the period ended September 30, 2021 were prepared in accordance with generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Operating results for the three and nine months ended September 30, 2021, are not necessarily indicative of the results that may be expected for the year ending December 31, 2021, or future years. All normal and recurring adjustments which, in the opinion of management, are necessary for a fair statement of the consolidated financial condition and results of operations have been included.

The year-end condensed consolidated balance sheet data was derived from audited financial statements for the year ended December 31, 2020. Certain information and disclosures normally included in the notes to the annual financial statements prepared in accordance with GAAP have been omitted from these interim condensed consolidated financial statements. These interim condensed consolidated financial statements should be read in conjunction with our latest Annual Report on Form 10-K for the year ended December 31, 2020 (“2020 Annual Report”).

The condensed consolidated financial statements include the accounts of ParkerVision, Inc. and its wholly-owned German subsidiary, ParkerVision GmbH, after elimination of all intercompany transactions and accounts.  

 

4. Accounting Policies

There have been no changes in accounting policies from those stated in our 2020 Annual Report, other than as described below. We do not expect any newly effective accounting standards to have a material impact on our financial position, results of operations or cash flows when they become effective.

We adopted Accounting Standards Update (“ASU”) 2020-06, “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” as of January 1, 2021. ASU 2020-06 simplifies accounting for convertible instruments, eliminating separation accounting for certain embedded conversion features. We used the modified retrospective method of adoption which allows for application of the guidance to transactions outstanding at the beginning of the fiscal year of adoption with the cumulative effect of the change being recorded as an adjustment to beginning retained earnings. Our adoption of ASU 2020-06 resulted in an increase to our long-term debt of approximately $0.8 million, a decrease in additional paid-in-capital of approximately $1.1 million, and an adjustment to our beginning accumulated deficit of

7


$0.3 million resulting from the elimination of the previously recognized beneficial conversion feature as a debt discount.

 

5. Revenue

We have an active monitoring and enforcement program with respect to our intellectual property rights that includes seeking appropriate compensation from third parties that utilize or have utilized our intellectual property without a license. As a result, we may receive payments as part of a settlement or in the form of court-awarded damages for a patent infringement dispute. We recognize such payments as revenue in accordance with Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers.”

During the three and nine months ended September 30, 2021, we recognized approximately $0.14 million in revenue from licensing and settlement agreements with third parties for their use of our technologies. Our performance obligations were satisfied, and therefore revenue recognized, upon receipt of proceeds and subsequent dismissal of all patent enforcement actions between the parties.

6. Loss per Common Share

Basic loss per common share is determined based on the weighted-average number of common shares outstanding during each period. Diluted loss per common share is the same as basic loss per common share as all common share equivalents are excluded from the calculation, as their effect is anti-dilutive.

We have shares underlying outstanding options, warrants, unvested restricted stock units (“RSUs”) and convertible notes that were excluded from the computation of diluted loss per share as their effect would have been anti-dilutive. These common share equivalents at September 30, 2021 and 2020 were as follows (in thousands):

September 30,

2021

2020

Options outstanding

23,724

12,248

Warrants outstanding

9,819

13,850

Unvested RSUs

-

291

Shares underlying convertible notes

20,757

23,807

54,300

50,196

 

7. Prepaid Expenses

Prepaid expenses consist of the following (in thousands):

September 30,

December 31,

2021

2020

Prepaid services

$

640

$

408

Prepaid bonds for German statutory costs

-

142

Prepaid insurance

32

21

Prepaid licenses, software tools and support

19

11

Other prepaid expenses

16

17

$

707

$

599

  

8


Prepaid services at September 30, 2021 and December 31, 2020 include approximately $0.6 million and $0.1 million, respectively of consulting services paid in shares of stock or warrants to purchase shares of stock in the future.

8. Intangible Assets

Intangible assets consist of the following (in thousands):

September 30,

December 31,

2021

2020

Patents and copyrights

$

14,826

$

14,948

Accumulated amortization

(12,939)

(12,778)

$

1,887

$

2,170

 

9. Leases

During the nine months ended September 30, 2021, we entered into a sublease agreement related to our Lake Mary office space. The sublease is accounted for as an operating lease and is for the remaining term of our original lease, through November 2022. Rental income recognized of $0.02 million for the three and nine months ended September 30, 2021, is included in “Other income” in the accompanying condensed consolidated statements of comprehensive loss.

10. Debt

Notes Payable

Related Party Note Payable

We have an unsecured promissory note of approximately $0.7 million payable to Sterne, Kessler, Goldstein, & Fox, PLLC (“SKGF”), a related party, for outstanding unpaid fees for legal services. Subsequent to September 30, 2021, SKGF agreed to amend the note in order to extend the final balloon payment due under the note from April 2022 to April 2023. The SKGF note, as amended, will continue to accrue interest at a rate of 4% per annum, requires repayments of principal and interest at a rate of $10,000 per month and will extend the final balloon payment into April 2023. We are currently in compliance with all the terms of the note. 

Secured Note Payable

Our secured note payable as of December 31, 2020 represented default interest accrued related to a note payable to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C (“Mintz”) for outstanding fees and expenses. Additionally, as of December 31, 2020, we had approximately $3.1 million in accounts payable to Mintz for outstanding fees and expenses.  We also had approximately $3.6 million in disputed legal fees and expenses billed by Mintz that we treated as a loss contingency that was not probable as of December 31, 2020 and accordingly, for which we recognized no expense in the consolidated financial statements.  On March 29, 2021, we entered into an agreement with Mintz to satisfy our outstanding obligations to Mintz.  Under the terms of the agreement, (i) Mintz waived all past defaults on the note resulting in a reversal of previously accrued interest, (ii) we paid Mintz a lump-sum payment of $3.0 million in satisfaction of all outstanding obligations including our accounts payable to Mintz and all disputed and unrecorded billings, and (iii) Mintz agreed to a significant reduction in future success fees that might be payable to Mintz from patent-related proceeds.

9


Unsecured Notes Payable

Unsecured notes payable at December 31, 2020 represented a Paycheck Protection Program loan of approximately $0.2 million received in May 2020. The loan was eligible for forgiveness provided that (i) we used the loan proceeds exclusively for allowed costs including payroll, employee group health benefits, rent and utilities and (ii) employee and compensation levels were maintained during the coverage period. We applied for loan forgiveness in April 2021 and the loan was forgiven in June 2021. The forgiveness of the loan was recognized as income and is included in “Other income” in the accompanying condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2021.

Convertible Notes

Our convertible notes represent 5-year promissory notes that are convertible, at the holders’ option, into shares of our common stock at fixed conversion prices. Interest payments are made on a quarterly basis and are payable, at our option, subject to certain equity conditions, in either cash, shares of our common stock, or a combination thereof. To date, all interest payments on the convertible notes have been made in shares of our common stock. We have recognized the convertible notes as debt in our condensed consolidated financial statements. The fixed conversion prices of certain of the notes were below the market value of our common stock on the closing date resulting in the recognition of a beneficial conversion feature that was recorded as a discount on the convertible notes at the note inception date, with a corresponding increase to additional paid in capital. Upon our adoption of ASU 2020-06 on January 1, 2021, the beneficial conversion feature was eliminated, resulting in an increase of $0.8 million to convertible debt and a cumulative adjustment to beginning accumulated deficit of $0.3 million, representing the discount amortization recognized prior to adoption of the new standard (see Note 4).

We have the option to prepay the majority of the notes, subject to a premium on the outstanding principal prepayment amount of 25% prior to the two-year anniversary of the note issuance date, 20% prior to the three-year anniversary of the note issuance date, 15% prior to the four-year anniversary of the note issuance date, or 10% thereafter.  The notes provide for events of default that include failure to pay principal or interest when due, breach of any of the representations, warranties, covenants or agreements made by us, events of liquidation or bankruptcy, and a change in control.  In the event of default, the interest rate increases to 12% per annum and the outstanding principal balance of the notes plus all accrued interest due may be declared immediately payable by the holders of a majority of the then outstanding principal balance of the notes.

10


Convertible notes payable at September 30, 2021 and December 31, 2020 consist of the following (in thousands):

Fixed

Principal Outstanding as of

Conversion

Interest

September 30,

December 31,

Description

Rate

Rate

Maturity Date

2021

2020

Convertible notes dated September 10, 2018

$0.40

8.0%

September 7, 2023

$

200

$

600

Convertible note dated September 19, 2018

$0.57

8.0%

September 19, 2023

425

425

Convertible notes dated February/March 2019

$0.25

8.0%

February 28, 2024 to March 13, 2024

850

1,300

Convertible notes dated June/July 2019

$0.10

8.0%

June 7, 2024 to July 15, 2024

340

340

Convertible notes dated July 18, 2019

$0.08

7.5%

July 18, 2024

700

700

Convertible notes dated September 13, 2019

$0.10

8.0%

September 13, 2024

50

50

Convertible notes dated January 8, 2020

$0.13

8.0%

January 8, 2025

450

450

Total principal balance

3,015

3,865

Less Unamortized discount

-

847

$

3,015

$

3,018

For the nine months ended September 30, 2021, convertible notes with a face value of $0.85 million were converted, at the option of the holders, into 2,800,000 shares of our common stock and we recognized interest expense of approximately $0.2 million related to the contractual interest which we elected to pay in shares of our common stock. For the nine months ended September 30, 2021, we issued approximately 215,000 shares of our common stock as interest-in-kind payments on our convertible notes.

At September 30, 2021, we estimate our convertible notes have an aggregate fair value of approximately $2.4 million and would be categorized within Level 2 of the fair value hierarchy.

Secured Contingent Payment Obligation

The following table provides a reconciliation of our secured contingent payment obligation, measured at estimated fair market value, for the nine months ended September 30, 2021 and the year ended December 31, 2020 (in thousands):

Nine Months Ended

September 30, 2021

Year Ended

December 31, 2020

Secured contingent payment obligation, beginning of period

$

33,057

$

26,651

Change in fair value

2,883

6,406

Secured contingent payment obligation, end of period

$

35,940

$

33,057

Our secured contingent payment obligation represents the estimated fair value of our repayment obligation to Brickell Key Investments, LP (“Brickell”) under a February 2016 funding agreement, as amended. Brickell is entitled to priority payments of 55% to 100% of proceeds received from all patent-related actions until such time that Brickell has been repaid its minimum return. The minimum return is determined as a multiple of the funded amount that increases over time. The estimated minimum return due to Brickell was approximately $47.2 million and $42.0 million as of September 30, 2021 and

11


December 31, 2020, respectively. In addition, Brickell is entitled to a pro rata portion of proceeds from specified legal actions to the extent aggregate proceeds from those actions exceed the minimum return. The range of potential proceeds payable to Brickell is discussed more fully in Note 11. As of September 30, 2021, we are in compliance with our obligations under this agreement.

We have elected to measure our secured contingent payment obligation at its estimated fair value based on probability-weighted estimated cash outflows, discounted back to present value using a discount rate determined in accordance with accepted valuation methods (see Note 11). The secured contingent payment obligation is remeasured to fair value at each reporting period with changes recorded in the condensed consolidated statements of comprehensive loss until the contingency is resolved.

Unsecured Contingent Payment Obligations

The following table provides a reconciliation of our unsecured contingent payment obligations, measured at estimated fair market value, for the nine months ended September 30, 2021 and the year ended December 31, 2020 (in thousands):

Nine Months Ended

September 30, 2021

Year Ended
December 31, 2020

Unsecured contingent payment obligations, beginning of period

$

5,222

$

-

Reclassification of other liabilities

-

1,003

Issuance of contingent payment rights

412

2,258

Change in fair value

113

1,961

Unsecured contingent payment obligations, end of period

$

5,747

$

5,222

Our unsecured contingent payment obligations represent amounts payable to others from future patent-related proceeds including (i) a termination fee due to a litigation funder and (ii) contingent payment rights issued to accredited investors in connection with equity financings (“CPRs”). We have elected to measure these unsecured contingent payment obligations at their estimated fair value based on probability-weighted estimated cash outflows, discounted back to present value using a discount rate determined in accordance with accepted valuation methods. The unsecured contingent payment obligations will be remeasured to fair value at each reporting period with changes recorded in the condensed consolidated statements of comprehensive loss until the contingency is resolved (see Note 11). During the nine months ended September 30, 2021, we received proceeds of $1.0 million from the sale of common stock with CPRs, of which approximately $0.4 million was allocated to the CPRs. Our aggregate maximum obligation under the unsecured contingent payment obligations is $10.8 million as of September 30, 2021.

12


11. Fair Value Measurements

The following tables summarize the fair value of our assets and liabilities measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020 (in thousands):

Fair Value Measurements

Total Fair Value

Quoted
Prices
in Active
Markets
(Level 1)

Significant
Other
Observable
Inputs
(Level 2)

Significant
Unobservable
Inputs
(Level 3)

September 30, 2021:

Liabilities:

Secured contingent payment obligation

$

35,940

$

-

$

-

$

35,940

Unsecured contingent payment obligations

5,747

-

-

5,747

 

Fair Value Measurements

Total Fair Value

Quoted
Prices
in Active
Markets
(Level 1)

Significant
Other
Observable
Inputs
(Level 2)

Significant
Unobservable
Inputs
(Level 3)

December 31, 2020:

Liabilities:

Secured contingent payment obligation

$

33,057

$

-

$

-

$

33,057

Unsecured contingent payment obligations

$

5,222

$

-

$

-

$

5,222

The fair values of our secured and unsecured contingent payment obligations were estimated using a probability-weighted income approach based on various cash flow scenarios as to the outcome of patent-related actions both in terms of timing and amount, discounted to present value using a risk-adjusted rate. We used a risk-adjusted discount rate of 14.41% at September 30, 2021, based on a risk-free rate of 0.41% as adjusted by 8% for credit risk and 6% for litigation inherent risk.


13


The following table provides quantitative information about the significant unobservable inputs used in the measurement of fair value for both the secured and unsecured contingent payment obligations at September 30, 2021, including the lowest and highest undiscounted payout scenarios as well as a weighted average payout scenario based on relative undiscounted fair value of each cash flow scenario.

Secured Contingent Payment Obligation

Unsecured Contingent Payment Obligations

Unobservable Inputs

Low

Weighted Average

High

Low

Weighted Average

High

Estimated undiscounted cash outflows (in millions)

$0.0

$50.2

$76.8

$0.0

$8.1

$10.8

Duration (in years)

0.3

2.5

3.3

1.3

2.5

3.3

Estimated probabilities

0%

21%

25%

25%

25%

25%

We evaluate the estimates and assumptions used in determining the fair value of our contingent payment obligations each reporting period and make any adjustments prospectively based on those evaluations. Changes in any of these Level 3 inputs could result in a significantly higher or lower fair value measurement.

 

12. Legal Proceedings

From time to time, we are subject to legal proceedings and claims which arise in the ordinary course of our business. These proceedings include patent enforcement actions initiated by us against others for the infringement of our technologies, as well as proceedings brought by others against us, including proceedings at the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (“PTAB”).

The majority of our litigation, including our PTAB proceedings, is being paid for through contingency fee arrangements with our litigation counsel as well as third-party litigation financing. In general, litigation counsel is entitled to recoup on a priority basis, from litigation proceeds, any out-of-pocket expenses incurred. Following reimbursement of out-of-pocket expenses, litigation counsel is generally entitled to a percentage of remaining proceeds based on the terms of the specific arrangement between us, counsel and our third-party litigation funder.

We were liable for costs assessed on infringement and validity cases in Germany in which we did not prevail. A portion of this liability was covered by bonds posted in Germany. As of September 30, 2021, our bonds have been fully released and all outstanding statutory court costs have been satisfied in full. We have no remaining litigation or related liabilities in Germany.

ParkerVision v. Qualcomm (Middle District of Florida)

We have a patent infringement complaint pending in the Middle District of Florida against Qualcomm Incorporated and Qualcomm Atheros, Inc. (collectively “Qualcomm”) seeking approximately $1.3 billion in damages for infringement of four of our patents (the “Qualcomm Action”).  HTC Corporation and HTC America, Inc. (collectively “HTC”) were also defendants in this case but we voluntarily dismissed our claims against HTC and HTC dismissed their related counter-claims against us in October 2020.  Qualcomm has pending counterclaims against us for non-infringement and invalidity for all patents in the case.  The case was filed in May 2014 and stayed in February 2016 pending decisions in other cases, including the appeal of a PTAB proceeding with regard to U.S. patent 6,091,940 (“the ‘940 Patent”) asserted in this case.  In March 2017, the PTAB ruled in our favor on three of the six petitions (the method claims), ruled in Qualcomm’s favor on two of the six petitions (the apparatus claims) and

14


issued a split decision on the claims covered in the sixth petition.  In September 2018, the Federal Circuit upheld the PTAB’s decision with regard to the ‘940 Patent and, in January 2019, the court lifted the stay in this case.  In July 2019, the court issued an order that granted our proposed selection of patent claims from four asserted patents, including the ‘940 Patent, and denied Qualcomm’s request to limit the claims and patents. The court also agreed that we may elect to pursue accused products that were at issue at the time the case was stayed, as well as new products that were released by Qualcomm during the pendency of the stay.  In September 2019, Qualcomm filed a motion for partial summary judgement in an attempt to exclude certain patents from the case, including the ‘940 Patent.  The court denied this motion in January 2020.  In April 2020, the court issued its claim construction order in which the court adopted our proposed construction for seven of the ten disputed terms and adopted slightly modified versions of our proposed construction for the remaining terms.  Due to the impact of COVID-19, a number of the scheduled deadlines in this case were moved including the trial commencement date which was rescheduled from December 2020 to May 2021.  We are seeking $1.3 billion in royalties owed to us by Qualcomm for its unauthorized use of our technology, based on a report submitted by our damages expert in this case in October 2020.  Such amount excludes additional amounts requested by us for interest and enhanced damages for willful infringement.  Ultimately, the amount of damages, if any, will be determined by a jury and the court.  Discovery was expected to close in December 2020; however, the court allowed us to designate a substitute expert due to medical issues with one of our experts in the case.  Accordingly, the close of discovery was delayed approximately one month until January 2021.  As a result of these delays, the court rescheduled the trial commencement date from May 3, 2021 to July 6, 2021.  In March 2021, the court further delayed the trial date citing backlog due to the pandemic, among other factors.  A new trial date has not yet been set although the court indicated the case was unlikely to be tried before November or December 2021.  Fact and expert discovery in this case are closed, expert reports have been submitted, and summary judgement and Daubert briefings have been completed by the parties.  Joint pre-trial statements were submitted in May 2021. In March 2021, the court granted Qualcomm’s motion to strike certain of our 2020 infringement contentions.  We filed a motion to clarify the court’s order and in July 2021, based on the court’s response to our motion to clarify, we filed a joint motion for entry of a judgement of non-infringement of our Patent No. 7,865,177 (“the ‘177 Patent”), subject to appeal.  A number of outstanding motions are pending decisions by the court. 

ParkerVision v. Apple and Qualcomm (Middle District of Florida)

In December 2015, we filed a patent infringement complaint in the Middle District of Florida against Apple Inc. (“Apple”), LG Electronics, Inc., LG Electronics U.S.A., Inc. and LG Electronics MobileComm U.S.A., Inc. (collectively “LG”), Samsung Electronics Co. Ltd., Samsung Electronics America, Inc., Samsung Telecommunications America LLC, and Samsung Semiconductor, Inc. (collectively “Samsung”), and Qualcomm alleging infringement of four of our patents. In February 2016, the district court proceedings were stayed pending resolution of a corresponding case filed at the International Trade Commission (“ITC”). In July 2016, we entered into a patent license and settlement agreement with Samsung and, as a result, Samsung was dismissed from the district court action. In March 2017, we filed a motion to terminate the ITC proceedings and a corresponding motion to lift the stay in the district court case. This motion was granted in May 2017. In July 2017, we filed a motion to dismiss LG from the district court case and re-filed our claims against LG in the District of New Jersey (see ParkerVision v. LG below).  Also in July 2017, Qualcomm filed a motion to change venue to the Southern District of California, and Apple filed a motion to dismiss for improper venue. In March 2018, the district court ruled against the Qualcomm and Apple motions. The parties also filed a joint motion in March 2018 to eliminate three of the four patents in the case in order to expedite proceedings leaving our U.S. patent 9,118,528 as the only remaining patent in this case. A claim construction hearing was held on August 31, 2018. In July 2019, the court issued its claim construction order in which the court adopted our proposed claim construction for two of the six terms and the “plain and ordinary meaning” on the remaining terms. In addition, the court denied a motion filed by Apple for summary judgment.  Fact discovery has closed in this case and a jury trial was scheduled to begin in August

15


2020.  In March 2020, as a result of the impact of COVID-19, the parties filed a motion requesting an extension of certain deadlines in the case.  In April 2020, the court stayed this proceeding pending the outcome of the Qualcomm Action.  

ParkerVision v. LG (District of New Jersey)

In July 2017, we filed a patent infringement complaint in the District of New Jersey against LG for the alleged infringement of the same four patents previously asserted against LG in Florida (see ParkerVision v. Apple and Qualcomm above). We elected to dismiss the case in Florida and re-file in New Jersey as a result of a Supreme Court ruling regarding proper venue. In March 2018, the court stayed this case pending a final decision in ParkerVision v. Apple and Qualcomm in the Middle District of Florida. As part of this stay, LG has agreed to be bound by the final claim construction decision in that case.

ParkerVision v. Intel (Western District of Texas)

In February 2020, we filed a patent infringement complaint in the Western District of Texas against Intel Corporation (“Intel”) alleging infringement of eight of our patents. The complaint was amended in May 2020 to add two additional patents. In June 2020, we requested that one of the patents be dropped from this case and filed a second case in the Western District of Texas that included this dismissed patent (see ParkerVision v. Intel II below). Intel’s response to our complaint was filed in June 2020 denying infringement and claiming invalidity of the patents. Intel has also filed a motion to transfer venue which was denied by the court. The court issued its claim construction ruling in January 2021 in which the majority of the claims were decided in our favor. The case was scheduled for trial beginning February 7, 2022. In April 2021, we filed an amended complaint to include additional Intel chips and products, including Wi-Fi devices to the complaint. The court suggested that, given the number of patents at issue, the case would be separated into two trials and, as a result of the added products, the first trial date will be scheduled in June 2022. Based on discussions with the court, we anticipate the second trial date will be scheduled to begin several months following the first trial.

ParkerVision v. Intel II (Western District of Texas)

In June 2020, to reduce the number of claims in ParkerVision v. Intel, we filed a second patent infringement complaint in the Western District of Texas against Intel that included one patent that we voluntarily dismissed from the original case. In July 2020, we amended our complaint adding two more patents to the case. In May 2021, we further amended our complaint to include additional Intel chips and products, including Wi-Fi devices. Two claim construction hearings were held and in July 2021, the court issued its claim construction order in which the majority of the claim terms were construed in our favor. Based on communications with the Court, the parties submitted a case schedule setting forth a final pretrial conference for October 2022, however this date may change dependent upon the timing of the second trial in the Intel I case discussed above.

Intel v. ParkerVision (PTAB)

Intel filed petitions for Inter Partes Review (“IPR”) against U.S. patent 7,539,474 (“the ‘474 Patent”), U.S. patent 7,110,444 (“the ‘444 Patent”) and U.S. patent 8,190,108 (“the ‘108 Patent”), all of which are patents asserted in our infringement cases against Intel. In January 2021, the PTAB issued its decision to institute IPR proceedings for the ‘444 Patent and the ‘474 Patent. An oral hearing was held on November 1, 2021 and final decisions from the PTAB on the ‘474 Patent and the ‘444 Patent are expected by late January 2022.

In July 2021, the PTAB issued its decision to institute IPR proceedings for the ‘108 Patent. We filed our response to this petition in October 2021 and an oral hearing is scheduled for April 2022. A final decision from the PTAB with respect to the ‘108 Patent is expected by July 2022.

16


Additional Patent Infringement Cases

ParkerVision filed a number of additional patent cases in the Western District of Texas in September and October 2020 including cases against (i) TCL Industries Holdings Co., Ltd, a Chinese company, TCL Electronics Holdings Ltd., Shenzhen TCL New Technology Co., Ltd, TCL King Electrical Appliances (Huizhou) Co., Ltd., TCL Moka Int’l Ltd. and TCL Moka Manufacturing S.A. DE C.V. (collectively “TCL”), (ii) Hisense Co., Ltd. and Hisense Visual Technology Co., Ltd (collectively “Hisense”), a Chinese company, (iii) Buffalo Inc., a Japanese company (“Buffalo”) and (iv) Zyxel Communications Corporation, a Chinese multinational electronics company headquartered in Taiwan, (“Zyxel”).  Each case alleges infringement of the same ten patents by products that incorporate modules containing certain Wi-Fi chips manufactured by Realtek and/or MediaTek.  Each of the defendants have filed responses denying infringement and claiming invalidity of the patents, among other defenses.

In September 2021, we dismissed the cases against Buffalo and Zyxel following satisfaction of the parties’ obligations under settlement and license agreements entered into in May 2021 and September 2021, respectively. The court held a Markman hearing on October 27, 2021 for the remaining defendants, Hisense and TCL, and issued its claim construction recommendations on October 29, 2021, in which nearly all of the claim terms were decided in our favor. The Hisense and TCL cases are expected to have a trial date in December 2022.  

In May 2021, we also filed a patent infringement case against LG Electronics, a South Korean company, in the Western District of Texas alleging infringement of the same ten patents.

TCL, et. al. v. ParkerVision (PTAB)

In May 2021, TCL, along with Hisense, filed petitions for Inter Partes Review (“IPR”) against U.S. patent 7,292,835 (“the ‘835 Patent”) and the ‘444 Patent, both of which are asserted in the infringement cases against these parties in the Western District of Texas. An institution decision is expected from the PTAB in late November 2021.

13. Stock Authorization and Issuance

Stock Authorization

On September 28, 2021, our shareholders approved an amendment to our amended and restated articles of incorporation to increase our authorized common shares from 140 million to 150 million.

Stock and Warrant Issuances – Equity Based Financings

Private Placements with Accredited Investors

In January 2021, we entered into securities purchase agreements with accredited investors for the sale of an aggregate of 2,976,430 shares of our common stock at a price of $0.35 per share for aggregate proceeds of $1.0 million. The securities purchase agreements include CPRs. Approximately $0.4 million of the proceeds were allocated to unsecured contingent payment obligations based on the initial fair value estimate of the CPRs (see Note 10). The shares were registered for resale on a registration statement that was declared effective on April 26, 2021 (File No. 333-255217).

In March 2021, we entered into securities purchase agreements with accredited investors for the sale of 3,230,942 shares of our common stock and 1,619,289 warrants at a price of $1.29 per common share for aggregate proceeds of approximately $4.2 million. The warrants have an exercise price of $1.75 per share and expire in March 2026. The shares, including the shares underlying the warrants, were registered for resale on a registration statement that was declared effective on April 26, 2021 (File No. 333-255217).

17


We used $3.0 million of the proceeds from this transaction to satisfy our obligations to Mintz (see Note 10).

Stock Issuances – Payment for Services

In January 2021, we amended our business consulting and retention agreement with Chelsea Investor Relations to increase the compensation for services over the remaining term and to extend the term of the agreement through February 2024.  As consideration for the amended agreement, we issued 500,000 shares of unregistered common stock in exchange for a nonrefundable retainer for services valued at approximately $0.33 million.  The value of the stock issued is being recognized as consulting expense over the term of the agreement. The shares were registered for resale on a registration statement that was declared effective on April 26, 2021 (File No. 333-255217).

In January 2021, we also issued 50,000 shares of our unregistered common stock, valued at approximately $0.03 million, as compensation for three months of shareholder awareness services provided by a third party.  In April 2021, we issued this third party an additional 50,000 shares of our unregistered common stock, valued at approximately $0.07 million as compensation for services over the remaining term of the agreement. In June 2021, we issued an additional 100,000 shares of our unregistered common stock, valued at approximately $0.12 million, to this same third-party as a retainer for services over a one-year term through May 31, 2022. The value of the shares issued will be recognized as consulting expense over the term of the agreement.

In April 2021, we issued 35,000 shares of our unregistered common stock to a consultant for services over a six-month term valued at approximately $0.04 million. The value of the shares issued will be recognized as consulting expense over the term of the agreement.  

In addition, from time to time, we issue restricted stock awards under our approved equity plans to third party consultants as share-based compensation. See “Non-Employee Compensation” in Note 14.

Common Stock Warrants

As of September 30, 2021, we had outstanding warrants for the purchase of up to 9.8 million shares of our common stock. The estimated grant date fair value of these warrants of $2.8 million is included in additional paid-in capital in our condensed consolidated balance sheets. As of September 30, 2021, our outstanding warrants have an average exercise price of $0.73 per share and a weighted average remaining life of approximately 3.2 years.

14. Share-Based Compensation

There has been no material change in the assumptions used to compute the fair value of our equity awards, nor in the method used to account for share-based compensation from those stated in our 2020 Annual Report.

For the three and nine months ended September 30, 2021, we recognized share-based compensation expense of approximately $0.75 million and $2.57 million, respectively. Share-based compensation is included in selling, general and administrative expenses in the accompanying condensed, consolidated statements of comprehensive loss.

As of September 30, 2021, there was $3.7 million of total unrecognized compensation cost related to all non-vested share-based compensation awards. The cost is expected to be recognized over a weighted-average remaining life of approximately 1.25 years.

18


During the nine months ended September 30, 2021, our board of directors (“Board”) amended our 2019 Long-Term Incentive Plan (“the 2019 Plan”) to increase the number of shares of common stock reserved for issuance under the 2019 Plan from 12 million to 27 million shares. The Board also approved awards under the 2019 Plan of 11.9 million nonqualified stock options to executives and other key employees and an aggregate of 1.1 million nonqualified stock options to non-employee directors. The options are exercisable at $0.54 per share, vest in eight equal quarterly installments commencing March 31, 2021, and expire on January 11, 2026.

Non-Employee Compensation

On March 9, 2021, we granted approximately 32,000 shares under our 2019 Plan to a consultant for business communications services over a 1-year term valued at approximately $0.05 million. On August 10, 2021, we granted 150,000 shares under our 2019 Plan to a consultant for services over a 1-year term valued at approximately $0.2 million. The value of the shares issued will be recognized as consulting expense over the terms of the agreements.  

19


ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

We believe that it is important to communicate our future expectations to our shareholders and to the public. This quarterly report contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, including, in particular, statements about our future plans, objectives, and expectations contained in this Item. When used in this quarterly report and in future filings by us with the Securities and Exchange Commission (“SEC”), the words or phrases “expects”, “will likely result”, “will continue”, “is anticipated”, “estimated” or similar expressions are intended to identify “forward-looking statements.” Readers are cautioned not to place undue reliance on such forward-looking statements, each of which speaks only as of the date made. Such statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results and those presently anticipated or projected, including the risks and uncertainties identified in our annual report on Form 10-K for the fiscal year ended December 31, 2020 (the “2020 Annual Report”) and in this Item 2 of Part I of this quarterly report. Examples of such risks and uncertainties include general economic and business conditions, competition, unexpected changes in technologies and technological advances, the timely development and commercial acceptance of new products and technologies, reliance on key suppliers, reliance on our intellectual property, the outcome of our intellectual property litigation and the ability to obtain adequate financing in the future. We have no obligation to publicly release the results of any revisions which may be made to any forward-looking statements to reflect anticipated events or circumstances occurring after the date of such statements.

Corporate Website

We announce investor information, including news and commentary about our business, financial performance and related matters, SEC filings, notices of investor events, and our press and earnings releases, in the investor relations section of our website (http://ir.parkervision.com). Additionally, if applicable, we webcast our earnings calls and certain events we participate in or host with members of the investment community in the investor relations section of our website. Investors and others can receive notifications of new information posted in the investor relations section in real time by signing up for email alerts and/or RSS feeds. Further corporate governance information, including our governance guidelines, board of directors (“Board”) committee charters, and code of conduct, is also available in the investor relations section of our website under the heading “Corporate Governance.” The content of our website is not incorporated by reference into this Quarterly Report or in any other report or document we file with the SEC, and any references to our website are intended to be inactive textual references only.

Overview

We have invented and developed proprietary radio frequency (“RF”) technologies and integrated circuits and license those technologies to third parties for use in wireless communication products. We have expended significant financial and other resources to research and develop our RF technologies and to obtain patent protection for those technologies in the United States of America (“U.S.”) and certain foreign jurisdictions. We believe certain patents protecting our proprietary technologies have been broadly infringed by others and therefore the primary focus of our business plan is the enforcement of our intellectual property rights through patent infringement litigation and licensing efforts. We currently have patent enforcement actions ongoing in various U.S. district courts against providers of mobile handsets and providers of smart televisions and other WiFi products and, in certain cases, their chip suppliers, for the infringement of several of our RF patents. We have made significant investments in developing and protecting our technologies, the returns on which are dependent upon the generation of future revenues for realization.

20


Liquidity and Capital Resources

We have incurred significant losses from operations and negative operating cash flows in every year since inception, largely as a result of our significant investments in developing and protecting our intellectual property, and have utilized the proceeds from sales of debt and equity securities and contingent funding arrangements with third-parties to fund our operations, including the cost of litigation.

For the nine months ended September 30, 2021, we incurred a net loss of approximately $9.0 million, and negative cash flows from operations of approximately $6.9 million. At September 30, 2021, we had cash and cash equivalents of approximately $0.8 million and an accumulated deficit of approximately $430.1 million. Additionally, a significant amount of future proceeds that we may receive from our patent enforcement and licensing programs will first be utilized to repay borrowings and legal fees and expenses under our contingent funding arrangements. These circumstances raise substantial doubt about our ability to continue to operate as a going concern for a period of one year following the issue date of our condensed consolidated financial statements.

We used cash for operations of approximately $6.9 million and $4.2 million for the nine months ended September 30, 2021 and 2020, respectively. The increase in cash used for operations from 2020 to 2021 is primarily due to the use of approximately $4.1 million in cash for the reduction of accounts payables and accrued expenses during the nine months ended September 30, 2021, as compared to a $1.3 million increase in accounts payable and accrued expenses during the nine months ended September 30, 2020. This increase in use of cash is somewhat offset by a reduction in cash-based operating costs from 2020 to 2021. For the nine months ended September 30, 2021, we received aggregate net proceeds from the sale of debt and equity securities, including the exercise of outstanding options and warrants, of approximately $6.1 million compared to approximately $5.5 million in proceeds received for the nine months ended September 30, 2020. We repaid approximately $0.07 million and $1.3 million, respectively in debt obligations during the nine months ended September 30, 2021 and 2020.

Patent enforcement litigation is costly and time-consuming and the outcome is difficult to predict. We expect to continue to invest in the support of our patent enforcement and licensing programs. All proceeds from litigation during the nine months ended September 30, 2021, were used to pay out-of-pocket legal expenses incurred by our counsel. Furthermore, we expect that revenue generated from patent enforcement actions and/or technology licenses in the remainder of 2021, if any, after deduction of payment obligations to third-party litigation funders, legal counsel, and other investors, will not be sufficient to cover our operating expenses. Therefore, our current capital resources are not sufficient to meet our short-term liquidity needs and we will be required to seek additional capital.

Our ability to meet both our short-term and long-term liquidity needs, including our debt repayment obligations, is dependent upon (i) our ability to successfully negotiate licensing agreements and/or settlements relating to the use of our technologies by others in excess of our contingent payment obligations to third-party litigation funders, legal counsel, and other investors; (ii) our ability to control operating costs, and (iii) our ability to raise additional capital from the sale of debt or equity securities or other financing arrangements. Failure to generate sufficient revenues, raise additional capital through debt or equity financings or contingent fee arrangements, and/or reduce operating costs will have a material adverse effect on our ability to meet our long-term liquidity needs and our ability to achieve our intended long-term business objectives.

21


Financial Condition

Our working capital increased approximately $3.8 million from December 31, 2020 to September 30, 2021. This increase in working capital is primarily the result of a $4.4 million decrease in accounts payable and accrued expenses, somewhat offset by a $0.9 million decrease in cash on hand at September 30, 2021 when compared to December 31, 2020. The decrease in accounts payable and accrued expenses included a $3.0 million payment to a law firm in settlement of outstanding fees and expenses and a reduction in potential success fees payable to the firm from future patent-related proceeds.

Our long-term liabilities increased approximately $3.1 million during the nine months ended September 30, 2021, primarily as a result of the $3.0 million increase in the estimated fair value of our secured and unsecured contingent payment obligations.

Results of Operations for Each of the Three and Nine Months Ended September 30, 2021 and 2020

Revenue

Licensing revenue was $0.14 million for the three and nine months ended September 30, 2021. We reported no licensing revenue for the three or nine-month periods ended September 30, 2020. We entered into patent licensing and settlement agreements with Buffalo, Inc. (“Buffalo”) and Zyxel Communications Corporation (“Zyxel”) in May 2021 and September 2021, respectively. We recognized revenue from these contracts during the three months ended September 30, 2021 when the parties performance obligations were met. The revenue from these agreements was fully offset against out-of-pocket expenses, included in selling, general and administrative expenses, incurred under our contingent fee agreements and therefore did not impact our cash flows. Although we do anticipate additional revenue to result from our licensing agreements and patent enforcement actions, the amount and timing is highly unpredictable and there can be no assurance that we will achieve our anticipated results.

Selling, General, and Administrative Expenses

Selling, general and administrative expenses consist primarily of litigation fees and expenses, personnel and related costs, including share-based compensation, for executive, Board, finance and accounting and technical support personnel for our patent enforcement program, and costs incurred for insurance and outside professional fees for accounting, legal and business consulting services.

Our selling, general and administrative expenses increased by approximately $0.6 million, or 40%, during the three months ended September 30, 2021 when compared to the same period in 2020. This is primarily the result of a $0.5 million increase in share-based compensation for the comparable periods.

Our selling, general and administrative expenses decreased by approximately $3.1 million, or 34%, during the nine months ended September 30, 2021 when compared to the same period in 2020. This decrease results, in part, from a number of one-time, noncash charges in 2020 including $1.8 million associated with an amendment to certain warrant agreements, $0.4 million from an amendment to our March 2020 equity transactions and $0.2 million for impairment of the right-of-use asset associated with our Lake Mary lease. In addition, our litigation fees and expenses decreased by approximately $2.3 million as a result of the stay in the Qualcomm case in Jacksonville, Florida. These decreases were partially offset by a $1.6 million increase in share-based compensation for the comparable periods.

The increase in our share-based compensation for both the three and nine-month periods ended September 30, 2021 is the result of share-based compensation expense attributed to nonqualified stock options awarded to executives, key employees and nonemployee directors in January 2021 as more fully discussed in Note 14 to our condensed consolidated financial statements. As of September 30, 2021, we

22


had $3.7 million of total unrecognized compensation cost related to all non-vested share-based compensation awards that is expected to be recognized over a period of approximately 1.25 years.

Change in Fair Value of Contingent Payment Obligations

We have elected to measure our secured and unsecured contingent payment obligations at fair value which is based on significant unobservable inputs. We estimated the fair value of our secured contingent payment obligations using a probability-weighted income approach based on the estimated present value of projected future cash outflows using a risk-adjusted discount rate. Increases or decreases in the significant unobservable inputs could result in significant increases or decreases in fair value. Generally, changes in fair value are a result of changes in estimated amounts and timing of projected future cash flows due to increases in funded amounts, passage of time, and changes in the probabilities based on the status of the funded actions.

For the nine months ended September 30, 2021, we recorded an aggregate increase in the fair value of our secured and unsecured contingent payment obligations of approximately $3.0 million, compared to an increase of approximately $3.5 million for the nine months ended September 30, 2020. The change in fair value for the nine months ended September 30, 2020 included a $1.4 million increase in the fair value of unsecured payment obligations resulting from a termination fee due on a failed litigation funding arrangement incurred in March 2020.

Off-Balance Sheet Transactions, Arrangements and Other Relationships

As of September 30, 2021, we had outstanding warrants to purchase approximately 9.8 million shares of our common stock. The estimated grant date fair value of these warrants of approximately $2.8 million is included in shareholders’ deficit in our condensed consolidated balance sheets. The outstanding warrants have a weighted average exercise price of $0.73 per share and a weighted average remaining life of approximately 3.2 years.

Critical Accounting Policies

There have been no changes in accounting policies from those stated in our 2020 Annual Report, except as described in Note 4 of the interim condensed consolidated financial statements. We do not expect any newly effective accounting standards to have a material impact on our financial position, results of operations or cash flows when they become effective.

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

ITEM 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

As of September 30, 2021, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our “disclosure controls and procedures,” as defined in Rule 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended (the “Exchange Act”).   Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that these disclosure controls and procedures were effective as of September 30, 2021.  

23


Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) under the Exchange Act that occurred during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. Legal Proceedings.

Reference is made to the section entitled “Legal Proceedings” in Note 12 to our unaudited condensed consolidated financial statements included in this quarterly report for a discussion of current legal proceedings, which discussion is incorporated herein by reference.

ITEM 1A. Risk Factors.

There have been no material changes from the risk factors disclosed in Item 1A of Part I of our Annual Report. In addition to the information in this quarterly report, the risk factors disclosed in our Annual Report should be carefully considered in evaluating our business because such factors may have a significant impact on our business, operating results, liquidity and financial condition.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

ITEM 3. Defaults Upon Senior Securities.

None.

ITEM 4. Mine Safety Disclosures.

Not applicable.

ITEM 5. Other Information.

None.


24


ITEM 6. Exhibits.

Exhibit Number

Description of Exhibit

3.1

Articles of Amendment to the Amended and Restated Articles of Incorporation (incorporated by reference from Exhibit 3.1 of Current Report on Form 8-K filed September 30, 2021)

31.1

Section 302 Certification of Jeffrey L. Parker, CEO*

31.2

Section 302 Certification of Cynthia L. French, CFO*

32.1

Section 906 Certification*

101.INS

Inline XBRL Instance Document*

101.SCH

Inline XBRL Taxonomy Extension Schema*

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase*

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase*

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase*

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase*

*Filed herewith


25


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ParkerVision, Inc.

Registrant

November 15, 2021

By:  

/s/Jeffrey L. Parker

Jeffrey L. Parker

Chairman and Chief Executive Officer

(Principal Executive Officer)

November 15, 2021

By:  

/s/Cynthia L. French

Cynthia L. French

Chief Financial Officer

(Principal Financial Officer and Principal

  Accounting Officer)

 

26

EXHIBIT 31.1



SECTION 302 CERTIFICATION

I, Jeffrey L. Parker, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of ParkerVision, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons fulfilling the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.



Ugust

 



 

Date: November 15, 2021

Name:/s/ Jeffrey L. Parker



Title: Chief Executive Officer (Principal Executive Officer)




EXHIBIT 31.2



SECTION 302 CERTIFICATION

I, Cynthia L. French certify that:

1.  I have reviewed this Quarterly Report on Form 10-Q of ParkerVision, Inc.;

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a  material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.  The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s  most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report)  that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.  The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons fulfilling the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.





 



 



 

Date: November 15, 2021

Name:/s/ Cynthia L. French



Title: Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)






EXHIBIT 32.1



SECTION 906 CERTIFICATION



CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report of ParkerVision, Inc. (the “Company”) on Form 10-Q, for the period ended September 30, 2021 as filed with the Securities and Exchange Commission (the “Report”), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:



1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.





 

Ugust 7

 



 

Dated: November 15, 2021

Name:/s/ Jeffrey L. Parker



Title: Chief Executive Officer (Principal



Executive Officer)







 



 



 

Dated: November 15, 2021

Name:/s/ Cynthia L. French



Title: Chief Financial Officer  (Principal



Financial Officer and Principal Accounting Officer)